keyword
MENU ▼
Read by QxMD icon Read
search

Metabolic syndrome antipsychotic

keyword
https://www.readbyqxmd.com/read/29609929/red-yeast-rice-ryr-supplementation-in-patients-treated-with-second-generation-antipsychotics
#1
Antonio Bruno, Gianluca Pandolfo, Manuela Crucitti, Giulia Maria Troili, Edoardo Spina, Rocco Antonio Zoccali, Maria Rosaria Anna Muscatello
OBJECTIVE: Second-generation antipsychotics (SGAs) have a negative impact on metabolic syndrome (MetS) risk factors for their effects on body weight and on metabolic parameters. Statins are widely used in the treatment of dyslipidemia; less is known on the ability of statins to treat SGAs-induced dyslipidemia, and nutraceutical approaches may represent promising strategies in SGAs-treated patients. Red Yeast Rice (RYR), the fermented product of the Aspergillaceae mold Monascus purpureus (red yeast) grown on white rice, has been shown to have a cholesterol-lowering effect which can be ascribed to monacolin K, although other active compounds may play a role management of hyperlipidemia...
April 2018: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/29593413/serum-levels-of-%C3%AE-hydroxybutyrate-and-pyruvate-metabolic-changes-and-cognitive-function-in-patients-with-schizophrenia-during-antipsychotic-treatment-a-preliminary-study
#2
Yu-Chi Huang, Pao-Yen Lin, Yu Lee, Chi-Fa Hung, Su-Ting Hsu, Chih-Ching Wu, Liang-Jen Wang
Background: β-hydroxybutyrate (β-HB) and pyruvate have been associated with the brain energy utilization, which may play a role in the pathophysiology of schizophrenia. In this prospective study, we aim to investigate the trends of β-HB and pyruvate levels, metabolic changes, and cognitive function in schizophrenia patients receiving antipsychotic treatment. Objective: We recruited 38 schizophrenia patients who had been treated with antipsychotics for 12 weeks, as well as 38 healthy age- and gender-matched subjects...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29587717/the-prevalence-of-metabolic-syndrome-in-patients-receiving-antipsychotics-in-qatar-a-cross-sectional-comparative-study
#3
Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Mahmoud Al-Zirie, Mohamed Osman Abdel Rahman, Angela Godwin, Noura Younes, Yahya Hani, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Reem El Sherbiny, Hassen Al-Amin
BACKGROUND: Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS. METHODS: A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114)...
March 27, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29587340/genetic-variations-associated-with-sleep-disorders-in-patients-with-schizophrenia-a-systematic-review
#4
REVIEW
Konstantinos Assimakopoulos, Katerina Karaivazoglou, Maria Skokou, Marina Kalogeropoulou, Panagiotis Kolios, Philippos Gourzis, George P Patrinos, Evangelia Eirini Tsermpini
Background: Schizophrenic patients commonly suffer from sleep disorders which are associated with acute disease severity, worsening prognoses and a poorer quality of life. Research is attempting to disentangle the complex interplay between schizophrenia and sleep disturbances by focusing not only on demographic and clinical characteristics, but also on the identification of genetic factors. Methods: Here, we performed a systematic literature review on the topic of genetic variations in sleep-disordered schizophrenic patients in an attempt to identify high quality investigations reporting scientifically sound and clinically useful data...
March 24, 2018: Medicines (Basel, Switzerland)
https://www.readbyqxmd.com/read/29564285/a-case-report-of-rapid-onset-hyponatremia-induced-by-low-dose-olanzapine
#5
Sethulakshmi Sreevalsam Anil, Badr Ratnakaran, Nisha Suresh
Hyponatremia has been reported with the use of psychotropic drugs. Olanzapine does not find much mention as a cause of hyponatremia in literature; however, it has been found to be the second most frequently reported atypical antipsychotic to cause it. We report a case of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion which occurred at a rapid onset following the administration of low-dose olanzapine during inpatient treatment of a patient with bipolar disorder. We would like to highlight our case for the need to be vigil about such fatal side complications apart from metabolic side effects of atypical antipsychotics...
October 2017: Journal of Family Medicine and Primary Care
https://www.readbyqxmd.com/read/29522591/-hypokalemic-rhabdomyolisis-and-schizophrenia
#6
Natalia Fantacone, Edgardo Carísimo, Pablo Landi, Eden Del Mar Walsöe, Daniel Fadel
The purpose of this report is to emphasize the necessity to periodically explore internal environment variables, as certain metabolic alterations often go unnoticed during antipsychotic treatment. Early detection of such alterations may prevent catastrophic syndromes. We will also stress the clinical relevance of cognitive perseverations in schizophrenic patients, as these often condition habits of consumption which can alter the internal environment. In this clinical case of a schizophrenic patient, a chain of events led to a catastrophic syndrome: a trivial home accident (fall from own height) developed into a condition characterized by oligoanuria, hypokalemia, creatine phosphokinase (CPK) elevation (125,000 IU / L) and acute renal failure with dialysis requirement...
July 2017: Vertex: Revista Argentina de Psiquiatriá
https://www.readbyqxmd.com/read/29519756/effects-of-cannabis-use-on-body-mass-fasting-glucose-and-lipids-during-the-first-12-months-of-treatment-in-schizophrenia-spectrum-disorders
#7
F Scheffler, S Kilian, B Chiliza, L Asmal, L Phahladira, S du Plessis, M Kidd, R M Murray, M Di Forti, S Seedat, R Emsley
While acute cannabis use stimulates appetite, general population studies suggest that chronic use is associated with reduced risk of obesity and other cardiometabolic risk factors. In this study we investigated changes in body mass index (BMI), fasting blood glucose and lipids, and rates of metabolic syndrome risk factors in cannabis users vs. non-users in 109 minimally treated patients with first-episode schizophrenia, schizophreniform or schizo-affective disorder who were treated according to a standardized treatment regime with depot antipsychotic medication over 12 months...
March 6, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29486959/cardio-metabolic-risk-and-its-management-in-a-cohort-of-clozapine-treated-outpatients
#8
Julia Margaret Lappin, Marlene Wijaya, Andrew Watkins, Rachel Morell, Scott Teasdale, Oscar Lederman, Simon Rosenbaum, Stephanie Dick, Philip Ward, Jackie Curtis
OBJECTIVE: To comprehensively assess cardio-metabolic risk factors and their management in a large sample of outpatients treated with clozapine. METHODS: Observational cross-sectional study of all clozapine users attending specialized clozapine monitoring outpatient clinics in three public hospitals in Sydney, Australia were approached to participate over the one-year period 01/10/2015-30/09/2016. Cardio-metabolic risk factors including metabolic syndrome, risk for future development of diabetes, smoking, physical activity, nutrition, and prescribed medications were assessed at face-to-face interview and through medical record review...
February 24, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29479787/cardiometabolic-risks-and-omega-3-index-in-recent-onset-bipolar-i-disorder
#9
Lawson R Wulsin, Thomas J Blom, Michelle Durling, Jeffrey A Welge, Melissa P DelBello, Caleb M Adler, Robert K McNamara, Stephen M Strakowski
OBJECTIVES: The aims of the present study were to characterize cardiometabolic risk factors in a cohort of bipolar disorder patients with limited exposure to psychotropic medications, and to evaluate their associations with mood symptoms and omega-3 polyunsaturated fatty acid (PUFA) blood levels. METHODS: Cardiometabolic risk assessments were compared in individuals with bipolar I disorder experiencing a first manic or mixed episode or an early depressive episode (n=117) and healthy subjects (n=56)...
February 26, 2018: Bipolar Disorders
https://www.readbyqxmd.com/read/29477703/latent-toxoplasma-gondii-infection-is-associated-with-decreased-serum-triglyceride-to-high-density-lipoprotein-cholesterol-ratio-in-male-patients-with-schizophrenia
#10
Marina Sagud, Suzana Vlatkovic, Dubravka Svob Strac, Mario Sviben, Maja Zivkovic, Maja Vilibic, Bjanka Vuksan-Cusa, Alma Mihaljevic-Peles, Nela Pivac
BACKGROUND: Previous studies suggested a complex association between Toxoplasma gondii (TG) infection and host lipid metabolism. Both TG infection and metabolic disturbances are very common in patients with schizophrenia, but this relationship is not clear. METHODS: In this cross-sectional study, we evaluated the association between TG seropositivity, serum lipid levels, body mass index (BMI) and metabolic syndrome (MetS) in 210 male inpatients with schizophrenia...
February 12, 2018: Comprehensive Psychiatry
https://www.readbyqxmd.com/read/29449054/second-generation-antipsychotic-induced-mitochondrial-alterations-implications-for-increased-risk-of-metabolic-syndrome-in-patients-with-schizophrenia
#11
Giselli Scaini, João Quevedo, Dawn Velligan, David L Roberts, Henriette Raventos, Consuelo Walss-Bass
Metabolic syndrome (MetS) is seen more frequently in persons with schizophrenia than in the general population, and these metabolic abnormalities are further aggravated by second generation antipsychotic (SGA) drugs. Although the underlying mechanisms responsible for the increased prevalence of MetS among patients under SGA treatment are not well understood, alterations in mitochondria function have been implicated. We performed a comprehensive evaluation of the role of mitochondrial dysfunction in the pathophysiology of drug-induced MetS in schizophrenia...
March 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29441581/genetic-polymorphisms-of-htr2c-lep-and-lepr-on-metabolic-syndromes-in-patients-treated-with-atypical-antipsychotic-drugs
#12
Apichaya Puangpetch, Weerapon Unaharassamee, Napa Jiratjintana, Napatrupron Koomdee, Chonlaphat Sukasem
OBJECTIVE: Single nucleotide polymorphisms in serotonin 2C receptor (HTR2C), leptin (LEP), and leptin receptor (LEPR) genes are reportedly associated with the presence of metabolic syndrome (MS). We investigated whether HTR2C:rs518147 (-697G/C), rs12836771 (A/G), LEP: rs7799039 (-2548G/A) and LEPR:rs1137101 (668A/G) are related to MS in psychotic disorder patients treated with atypical antipsychotics. METHODS: A cross-sectional study including 200 patients was conducted; genetic polymorphisms in HTR2C (rs518147 and rs12836771), LEP (rs7799039) and LEPR (rs1137101) were genotyped...
February 13, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29397899/sodium-benzoate-a-d-amino-acid-oxidase-inhibitor-added-to-clozapine-for-the-treatment-of-schizophrenia-a-randomized-double-blind-placebo-controlled-trial
#13
Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang, Hsien-Yuan Lane
BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine...
December 26, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/29320364/cardiometabolic-effects-of-psychotropic-medications
#14
REVIEW
Oluchi Abosi, Sneha Lopes, Samantha Schmitz, Jess G Fiedorowicz
Background Many psychiatric disorders including schizophrenia, bipolar disorder and major depression convey an excess burden of cardiovascular morbidity and mortality. The medications used to treat these conditions may further adversely affect cardiovascular risk and exacerbate health disparities for vulnerable populations. There is a clinical need to appreciate the cardiometabolic adverse effects of psychotropic medications. Methods This paper reviews the most relevant cardiometabolic effects of psychotropic medications, organized around the components of metabolic syndrome...
January 10, 2018: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/29285684/socioeconomic-disparities-and-metabolic-risk-in-veterans-with-serious-mental-illness
#15
Stanley N Caroff, Shirley H Leong, Daisy Ng-Mak, E Cabrina Campbell, Rosalind M Berkowitz, Krithika Rajagopalan, Chien-Chia Chuang, Antony Loebel
Socioeconomic disparities were assessed in predicting metabolic risk among veterans with serious mental illness. Veterans with schizophrenia, schizoaffective, or bipolar disorders were identified in VISN 4 facilities from 10/1/2010 to 9/30/2012. Differences between patients with and without metabolic syndrome were compared using t-tests, Chi square tests and multivariate logistic regressions. Among 10,132 veterans with mental illness, 48.8% had metabolic syndrome. Multivariate logistic regression analysis confirmed that patients with metabolic syndrome were significantly more likely to be older, male, African-American, married, and receiving disability pensions but less likely to be homeless...
December 28, 2017: Community Mental Health Journal
https://www.readbyqxmd.com/read/29220825/effects-of-nutritional-education-on-weight-change-and-metabolic-abnormalities-among-patients-with-schizophrenia-in-japan-a-randomized-controlled-trial
#16
Norio Sugawara, Toyoaki Sagae, Norio Yasui-Furukori, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Takuro Sugai, Hiroshi Matsuda, Yutaro Suzuki, Yuji Ozeki, Kurefu Okamoto, Toshiyuki Someya
OBJECTIVE: Patients with schizophrenia have a higher prevalence of metabolic syndrome (MetS) than the general population. Minimizing weight gain and metabolic abnormalities in a population with an already high prevalence of obesity is of clinical and social importance. This randomized controlled trial investigated the effect of monthly nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan. METHODS: From July 2014 to December 2014, we recruited 265 obese patients who had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder...
February 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29210867/antipsychotic-polypharmacy-and-its-relation-to-metabolic-syndrome-in-patients-with-schizophrenia-an-egyptian-study
#17
Dina M Aly El-Gabry, Karim Abdel Aziz, Tarek Okasha, Hanan Azzam, Ahmed Okasha
PURPOSE/BACKGROUND: Few studies have examined the relationship between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. Some studies suggest that antipsychotic polypharmacy may be associated with greater metabolic risk, whereas other studies suggest that this is uncertain. To date, there have been no studies in Egypt or the Arab world that have investigated this relationship. We sought to compare subjects with schizophrenia receiving antipsychotic polypharmacy and monotherapy as regards metabolic outcomes and to investigate medication-related factors associated with metabolic syndrome...
February 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29197134/assessment-of-cardiovascular-risk-in-an-italian-psychiatric-outpatient-sample-a-chart-review-of-patients-treated-with-second-generation-antipsychotics
#18
Elena Severi, Maria Ferrara, Enrico Tedeschini, Francesca Vacca, Francesco Mungai, Rocco Amendolara, Flavia Baccari, Fabrizio Starace
Despite the call by the scientific community for a systematic monitoring of physical health in people with psychiatric illnesses, national and international audits have reported poor quality of cardiovascular risk assessments and management in this vulnerable population. Available evidence indicates that in people affected by mental illness, life expectancy is reduced by 10-20 years, mainly due to cardiovascular accidents and metabolic syndrome (MetS)-related diseases. The primary aim of the present study was to evaluate the accuracy of cardiovascular risk monitoring in an outpatient sample of patients taking second-generation antipsychotics...
December 2, 2017: International Journal of Mental Health Nursing
https://www.readbyqxmd.com/read/29189863/-the-association-of-schizophrenia-with-chronic-non-transmissible-diseases
#19
REVIEW
Gricel Orellana, Matías Rodríguez, Nicolás González, Eduardo Durán
The life expectancy of patients with schizophrenia (SCH) is 11 to 20 years less than the general population. There is an association between SCH and various diseases and chronic conditions, highlighting the cardio-metabolic diseases. This association has been attributed to the use of antipsychotics, however, evidence has also shown intrinsic susceptibility of schizophrenic patients the development of chronic conditions. This review aims to update knowledge about chronic conditions such as cardiometabolic risk and sleep, bone and kidney disorders related to SCH...
August 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29179831/improving-metabolic-monitoring-rate-for-young-people-aged-35-and-younger-taking-antipsychotic-medications-to-treat-a-psychosis-a-literature-review
#20
REVIEW
Gin-Liang Chee, Dianne Wynaden, Karen Heslop
Young people aged 35 and younger who are taking antipsychotic medications to treat a psychosis are a high risk for developing metabolic syndrome due to the adverse effects of the medications. This paper reports the finding of a review of literature to identify interventions to improve metabolic monitoring rates in this group. A review of 478 studies identified 15 articles which met the inclusion criteria. Five articles reported single-intervention studies and the remaining integrated two or more interventions to improve uptake level of metabolic monitoring...
December 2017: Archives of Psychiatric Nursing
keyword
keyword
73394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"